PTPI
Petros Pharmaceuticals, Inc.
Set alert
- YTD
- -75.00%
- 1 year
- -90.00%
- Open
- 0.002
- Prev close
- 0.002
- Mkt cap
- 84.74K
- Vol
- 64.10K
- Avg vol
- 134.13K
- EPS
- 0.08
- P/E
- 0.03
- Div yield
- 0.00%
More statistics
- Low
- 0.002
- High
- 0.0024
- Forward P/E
- -0.26
- Beta
- 2.28
- Short ratio
- 0.72
- Inst. own
- 2.29%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.32284
- 200-d avg
- 0.5288
- 1y target
- 0.00
Key statistics
- Market cap
- 2.85M
- Enterprise value
- 3.99M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.69
- Price / book
- 0.07
- EPS (TTM)
- -3.80
- Beta
- 2.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -171.24%
- Revenue (TTM)
- 4.12M
- Revenue growth
- -28.70%
- Free cash flow
- -4.10M
- Total cash
- 7.46M
- Total debt
- 7.74M
- Return on equity
- -63.77%
- Shares outstanding
- 10.01M
- Short % of float
- 2.19%
- 50-day average
- 0.32284
- 200-day average
- 0.5288
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.53 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.37 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -2.05 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -2.17 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -2.31 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -1.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 8, 2023 | Maxim Group | init | — | Buy |
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- petrospharma.com
News
- Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
- Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
- Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
Your note
Sign in to keep a note on PTPI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERNSTEIN BRUCE T. | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,346 |
| BOCTOR FADY | Officer | Stock Award(Grant) | Dec 20, 2023 | 49,645 |
| BRADLEY GREG | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,314 |
| SILVERMAN JOSHUA N. | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 11,237 |
| WALKER WAYNE REMELL | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,314 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.44% | 44,221 | 12.59K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.37% | 37,517 | 10.68K | Sep 29, 2024 |
| Vanguard Group Inc | 0.32% | 31,811 | 9.05K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.32% | 32,284 | 9.19K | Sep 29, 2024 |
| Blackrock Inc. | 0.16% | 16,128 | 4.59K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 3,255 | 926 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.35% | 35,024 | 9.97K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.32% | 31,811 | 9.05K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 1,160 | 330 | Oct 30, 2024 |